InterVenn’s Melanoma Test Helps Oncologists Plan for Treatment
InterVenn's new melanoma test is commercially available as a glycoproteomics LDT that aids oncologists in planning treatment for melanoma.
InterVenn's new melanoma test is commercially available as a glycoproteomics LDT that aids oncologists in planning treatment for melanoma.
Bluestar Genomics’ technology can noninvasively detect cancers and help identify the underlying biology of the disease using epigenetic markers.
The test will help patients receive a definitive diagnosis for suspicious skin lesion biopsies.
The panel accurately and sensitively detects more than 1,600 variants of clinical significance.
Read MoreAnti-idiotypic antibodies will enable monitoring of for pembrolizumab and nivolumab levels in cancer patients undergoing treatment.
Read MoreCirculating tumor DNA is a reliable biomarker of tumor progression following immunotherapy treatment.
Read MoreProtagen and Gustave Roussy will partner to utilize Protagen’s SeroTag technology to help identify biomarkers that predict and monitor immune-related adverse events in cancer patients treated with checkpoint inhibitors.
Read MorePresenting an evaluation of the GeneReader next-generation sequencing (NGS) system, the article assesses the performance of the system in comparison with an alternative NGS technology.
Read MoreStudy results have demonstrated that a test based on a protein signature associated with patient outcomes in metastatic melanoma can effectively predict survival among patients receiving programmed cell death-1 antibodies.
Read MoreLed by investigators at the Translational Genomics Research Institute, researchers have identified a protein target that opens a window into acral lentiginous melanoma and may aid in diagnosis.
Read MoreEarly data suggests the test’s clinical potential for guiding anti-PD-1 therapy.
Read MoreAfter its ASH 2014 debut, the RainDance HemOnc Consortium, an international panel of clinical research experts, will focus on developing assays for liquid biopsy research of myeloid disorders.
Read MoreThe Sentosa SA NRAS PCR test from Vela Diagnostics is the only automated NRAS qPCR test available to detect mutations related to melanoma and thyroid cancers.
Read MoreThe real-time PCR test offers clinicians a standardized, reproducible, and clinically validated method to select patients with BRAF-mutant unresectable or metastatic melanoma that may be suitable for treatment with Tafinlar and Mekinist.
Read MoreThe vast majority of parents who tested positive for a genetic mutation that increases the risk of melanoma support genetic testing of their children or grandchildren.
Read More